AstraZeneca is a company with a turbulent history but, for now, a promising future. We take a look at the company's story, from its creation as a merger of two equals, to its recent major ...

When Oxford University developed the AstraZeneca vaccine, Dr Sue Pavord, a consultant haematologist, was so eager for it to ...

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.

AstraZeneca (NASDAQ:AZN) is one of the biggest players in the healthcare sector, whose medicines save the lives of tens of thousands of people every year. In this article, I will share six reasons ...

Jan 17 (Reuters) - AstraZeneca (AZN.L), opens new tab has overhauled its local management in China, replacing Michael Lai with Alex Lin as the country's general manager, the Financial Times ...

WILMINGTON, Del., January 17, 2025--AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with ...

A targeted cancer therapy from AstraZeneca’s alliance with Daiichi Sankyo is now FDA approved to treat certain cases of advanced breast cancer, giving the British pharmaceutical giant another ...

A next-generation form of chemotherapy from AstraZeneca and Daiichi Sankyo has won Food and Drug Administration authorization for a form of breast cancer, the first U.S. approval for a drug for ...

AstraZeneca still trades at a premium valuation, but several factors limit its upside potential in the next visible period. There are three negative takeaways from China. IRA could also ...

Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA approvals. Calquence, in combination with chemotherapy bendamustine and ...